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The extracellular matrix is a key regulator of cell 
and tissue function. Traditionally, the extracellular 
matrix is considered as a physical scaffold that 
binds cells and tissues together (5). However, the 
extracellular matrix is a dynamic structure that 
interacts with cells and generates signals through 
feedback loops to control the behavior of cells. Thus, 
extracellular matrix macromolecules are bioactive 
and modulate cellular events such as adhesion, 
migration, proliferation, differentiation, and survival 
(3). Additionally, extracellular matrix molecules are 
strictly organized and this organization determines 
the bioactivity of it. Even minor alterations in a 
single extracellular matrix component can lead 
not only to altered physicochemical properties of 
tissues but also to changes in cellular phenotype 
and cell-matrix interactions. It has been proposed 
that these changes in extracellular matrix structure 
and bioactivity in tissue function ultimately lead to 
development of disease (6). 
Parasites and neoplastic cells, during tissue 
invasion or tumor dissemination, modify extracellular 
matrix in order to modulate host immune responses 
and facilitate the mobilization inside the tissues (2,4). 
Trypanosoma cruzi, the causative agent of Chagas 
disease, induces changes in extracellular matrix 
in different tissues, for example in myocardium (7) 
and in human placental chorionic villi (4). Neoplastic 
cells modify host microenvironment that undergoes 
extensive changes during the evolution and 
progression of cancer. This involves the generation 
of cancer-associated fibroblasts, which, through 
release of growth factors and cytokines, lead to 
enhanced angiogenesis, increased tumor growth 
and invasion. The altered fibroblast phenotype 
also contributes to the development of an altered 
extracellular matrix. The inflammatory infiltrate 
associated with many solid tumors also modulates 
tumor function, having both anti- and pro-tumor 
effects (1). 
We have analyzed changes in extracellular 
matrix induced by T. cruzi in human placental 
chorionic villi as well as those induced in tumor 
stroma and neighboring connective tissue by oral 
squamous cell carcinoma and by salivary papillary 
cystadenocarcinoma.
Extracellular matrix changes induced by 
Trypanosoma cruzi in human placental 
chorionic villi 
The human placenta is classified as a hemochorial 
villous placenta in which the free chorionic villi are 
the functional units. These chorionic villi are formed 
by the trophoblast and the villous stroma. The 
trophoblast is formed by a single multinucleated 
cell layer (syncytiotrophoblast) which contacts 
maternal blood in the intervillous space, and by 
the cytotrophoblast which contains replicating 
progenitor cells. The trophoblast is separated by 
a basal lamina from the villous stroma, which is 
connective tissue containing vascular endothelium, 
fibroblasts, and macrophages. Trophoblast, basal 
laminae, and villous stroma with endothelium of 
fetal capillaries form the placental barrier that 
must be crossed by different pathogens, including 
T. cruzi, in order to infect the fetus during vertical 
transmission (4).
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Trypanosoma cruzi induces syncytiotrophoblast 
destruction and detachment, selective disor-
ganization of basal lamina and disorganization of 
collagen I in the connective tissue of villous stroma. 
These effects can be observed in placentas of 
mothers with chronic asymptomatic Chagas 
disease as well as in ex vivo infected chorionic villi 
explants. In the chorionic villi explants these effects 
are a function of the number of parasites used for 
the infection. The destruction of the extracellular 
matrix is product of activation of proteases of the 
parasite (cruzipain) and matrix metalloproteases 
(MMP) of the placental tissue. Trypanosoma cruzi 
induces expression and activity of MMP-2 and 
MMP-9 in chorionic villi explants. Inhibition of the 
proteases prevents partially the extracellular matrix 
destruction induced by the parasite. 
It has been proposed that extracellular matrix 
alterations produced by T. cruzi not only promote its 
motility in tissues and its entrance into cells, but also 
alter the presence of cytokines and chemokines, 
which in turn permit this parasite to modulate 
and escape both the inflammatory response and 
the immune response (4,7). Alternatively, these 
changes in extracellular matrix function may be 
part of local placental defense mechanisms, which 
could explain both the low presence of parasites in 
the placenta and the low incidence of congenital 
Chagas disease.
Extracellular matrix changes in neoplastic 
lesions with different degree of malignancy
Cancer cell migration and invasion into adjacent 
connective tissue depends on extracellular matrix, 
which provides a physical scaffold for cell adhesion 
and migration. Proteolysis of the extracellular 
matrix regulates cellular migration by modifying 
the structure of the extracellular matrix scaffold 
and by releasing extracellular matrix fragments 
with biological functions. Extracellular matrix 
proteolysis is therefore tightly controlled in normal 
tissues but typically deregulated in tumors (5). 
Changes in extracellular matrix in areas of invasive 
tumor front are used in some systems to classify 
neoplastic lesion of epithelia origin, like the Bryne’s 
multifactorial grading system for the invasive tumor 
front (8). 
In highly invasive (poor differentiated) oral 
squamous cell carcinoma destruction of basal 
lamina and disorganization of collagen I in adjacent 
connective tissue is present. Contrarily, in low 
grade papillary cystadenocarcinoma and well 
differentiated oral squamous cell carcinoma only 
in some focal areas a slight discontinuity can 
be observed and the collagen I in the adjacent 
connective tissue is well organized.
Therefore the organization of the extracellular 
matrix can prevent or facilitate the tumor invasion 
and dissemination. Poor differentiated tumors 
modify the extracellular matrix in order to facilitate 
the invasion process. Contrarily, well differentiated 
tumors are not able to modify the extracellular 
matrix and the tissue can impair the invasion and 
dissemination of the neoplastic lesion.
 In summary, parasite and tumors induces 
extracellular matrix responses that can facilitate 
or impair tissue invasion. The extracellular matrix 
response depends on the type of aggression 
(parasite, type of tumor) as well as of the type of 
tissue that is being challenged.
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Trypanosoma cruzi calreticulin (TcCRT) is a 
parasite virulence factor that participates in 
important aspects of the T. cruzi interactions with its 
vertebrate host. Among the known parasite surface 
molecules participating in infectivity, TcCRT, after 
being translocated from the endoplasmic reticulum 
to the area of flagellar emergence, recruits 
complement C1 and interferes with the ability of 
the associated C1r and C1s serine proteases to 
activate the central component C4. By recruiting 
C1, parasite surface TcCRT also promotes early 
C1-dependent phagocytosis, a phenomenon 
reminiscent of what human apoptotic cells do. 
In spite of the evolutionary distance between 
trypanosomatids and mammals, the phagocytic 
removal of apoptotic and tumor cells by macrophages 
and dendritic cells has also been proposed as 
strongly dependent on C1 that is recruited by 
membrane-translocated vertebrate CRT. C1 affinity 
for antigen-aggregated immunoglobulins, and 
TcCRT immunogenicity, will also contribute to a 
state of self-sustained in vivo parasite infectivity. 
The interaction between TcCRT and C1 can be 
partially reversed by F(ab´)2 fragments (bivalent 
antigen-specific immunoglobulin fragments, devoid 
of their Fc portions and thus unable to bind the first 
complement component C1 prepared from anti-
TcCRT Igs, thus reversing the TcCRT-promoted 
infectivity. 
On the other hand, externalized TcCRT, by itself, 
will bind to endotheliocytes from both arterial and 
venous emerging capillaries, as tested in a variety 
of assays in four vertebrate species. Inhibition of 
angiogenesis will follow, a phenomenon that could 
explain the capacity of this molecule to inhibit tumor 
growth in vivo and, perhaps the antitumor effects 
reported for the parasite infection in experimental in 
vivo set ups. All these properties map to the TcCRT 
N-terminal domain.
The combined anti-angiogenic and anti-
complement TcCRT effects may be anti-
inflammatory, thus inhibiting the immune response 
against the parasite. 
Considering these results altogether, it could be 
speculated that the interactions among TcCRT, 
complement, and endothelial cells are calibrated 
evolutionary adaptations aimed at protecting both 
the parasite and the host, thus promoting long-term 
interplays. 
These findings open possibilities for the 
development of new experimental anti-tumor 
strategies, especially if we consider that TcCRT 
displays stronger anti-angiogenic and anti-tumor 
effects than its human counterpart. Whether the 
anti-angiogenic properties were consolidated 
first in the parasite chaperone molecule, and 
HuCRT conserved some of these properties as 
an evolutionary relic or, alternatively, the parasite 
hijacked this activity from its vertebrate host, 
remains an open question. Although in vivo, both 
T. cruzi infection and TcCRT treatment, inhibit 
tumor development, it is not possible at present 
to causally associate both phenomena (i.e., that 
T. cruzi infection inhibits tumor growth through the 
anti-angiogenic T. cruzi capacity). 
In synthesis, it could be proposed that not all 
consequences of host-parasite interactions are 
deleterious to the former, and that the parasite has 
developed cellular and molecular strategies that 
could benefit the host, with indirect benefits for the 
aggressor.
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Aproximadamente, 10 a 30 % de los pacientes 
infectados con Trypanosoma cruzi desarrollan 
manifestaciones típicas de la fase crónica, siendo 
la más importante la cardiopatía chagásica, 
principal causa de muerte en esta enfermedad. 
La cardiopatía chagásica crónica se presenta con 
síntomas y signos que derivan de una falla cardiaca, 
la cual es usualmente biventricular y, además, se 
presenta con arritmias complejas, tromboembolia 
y muerte súbita (1). Al cabo de cinco años de 
establecido el diagnóstico, la mortalidad alcanza el 
50 % de los pacientes infectados. 
La fisiopatología de la cardiopatía chagásica 
crónica es compleja y multifactorial. Sin embargo, 
se han postulado cuatro mecanismos principales 
que explican esta alteración: 
 i) daño al miocardio, dependiente del parásito,  
 daño al miocardio, mediado por la respuesta  
 inmunitaria, 
 ii) disautonomía cardiaca, y 
 iv) anormalidades microvasculares e isquemia (2). 
Evidentemente, la persistencia del parásito 
puede provocar daño directo en los miocitos, pero 
también provoca una respuesta inmunológica e 
inflamatoria permanentes que, necesariamente, 
alteran la arquitectura cardiaca por una miocarditis 
persistente. 
Por otro lado, el sistema autónomo está alterado 
debido a la presencia de autoanticuerpos contra 
receptores adrenérgicos y colinérgicos del 
miocardio en pacientes con enfermedad de 
Chagas, lo que provoca alteraciones fisiológicas, 
morfológicas, enzimáticas y moleculares, y conduce 
a denervación parasimpática y activación simpática, 
lo que genera la ausencia de mecanismos que 
regulen el ritmo cardiaco. 
Finalmente, en diversos estudios se ha observado 
que hay anormalidades microvasculares que 
incluyen constricción vascular focal, proliferación 
microvascular y trombos oclusivos de plaquetas 
en arterias coronarias, que llevan a isquemia. Es 
más, en corazones chagásicos se ha observado 
distribución focal de necrosis celular y fibrosis 
intersticial, similar a lo observado en modelos 
experimentales de isquemia y reperfusión. 
Existe una relación directa entre las plaquetas 
y el endotelio inflamado cuando éste es activado. 
La respuesta endotelial a la infección por T. cruzi 
incluye activación del factor de necrosis NF-κB, 
expresión de moléculas de adhesión (E-selectina, 
VCAM-1, ICAM-1) y aumento en la sensibilidad 
celular del endotelio a la infección, además de 
lo cual, favorece la agregación plaquetaria en la 
superficie endotelial y la trombosis microvascular. 
En el proceso de agregación plaquetaria, también 
intervienen directamente prostanoides, como el 
tromboxano A2 (2). Sin embargo, la participación 
de prostaglandinas, como la prostaglandina E2 
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(PGE2), en la fisiopatología de la enfermedad de 
Chagas es más compleja, pues no sólo participan 
en la contención de la infección, sino también en 
procesos de evasión de la respuesta inmunitaria y 
en el proceso inflamatorio propio de la miocarditis 
chagásica. Es más, el tromboxano por sí mismo es 
vasoconstrictor y proinflamatorio y, por ello, puede 
contribuir al daño isquémico y a la cardiopatía (3). 
Los estudios realizados en nuestro laboratorio 
han revelado que en un modelo de ratón de la 
enfermedad de Chagas crónica, hay disfunción 
endotelial, manifestada principalmente por cambios 
en la morfología de la arquitectura vascular y del 
miocardio, y la expresión de las moléculas de 
adhesión endotelial: e-selectina, VCAM-1, ICAM-1. 
Por otro lado, se determinaron los niveles séricos de 
TXA2 y PGE2 y se correlacionaron con la expresión 
de COX y sus isoformas COX1 y COX2.
Así, se observaron cambios histológicos 
indicativos de miocarditis crónica, principalmente 
por las características del infiltrado inflamatorio, 
asociado a engrosamiento de las paredes de 
arteriolas y entrecruzamiento y desorganización 
de las fibras miocárdicas, alteraciones evidentes 
a partir del día 24 después de la infección y que 
se mantiene luego de 90 días. La infección fue 
establecida con la inyección intraperitoneal de 500 
tripomastigotes sanguíneos. El análisis inmuno-
histoquímico de corazones infectados con T. cruzi, 
reveló expresión de moléculas de adhesión como 
ICAM, VCAM y e-selectina; además, aumentó el 
nivel circulante de la fracción soluble de ICAM 
(sICAM), que también es un marcador de daño 
endotelial.
Por otro lado, mediante estudios de Western blot, 
se pudo comprobar que en la cardiopatía chagásica 
la isoforma predominante es la ciclooxigenasa de 
tipo 2, tanto en modelos in vivo como in vitro de 
la infección. Además, esta actividad puede ser 
inhibida por la aspirina, lo cual es un hallazgo 
interesante, por cuanto se ha establecido que la 
aspirina inhibe predominantemente a la isoforma 
constitutiva. 
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Trypanosoma cruzi, a parasitic protozoan, is the 
etiological agent of Chagas’ disease, an endemic 
pathology in Latin America. The transmission of the 
disease is produced by an infected triatomine insect 
that upon feeding on mammalian blood, deposits 
feces with infective parasites (trypomastigotes) 
which enter the mammalian body mainly through the 
skin wound produced by the insect. Upon entering 
the body, the parasites invade macrophages 
taking a round, replicative form, the amastigote. 
After replication, the amastigotes transform back 
to trypomastigotes that invade heart, ganglia and 
other tissues. Drugs used for treatment of Chagas 
disease are mainly active in acute infection and 
present collateral effects.
Trypanosoma cruzi is exposed to ROS/NOS in 
its three cellular forms. Thus, in the intestine of 
the triatomine after a blood meal, Fe+2 is formed 
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and produces reactive species through the Fenton 
reaction affecting epimastigotes. On the other hand, 
trypomastigotes are under the attack of ROS/NOS 
in the parasitophore vesicle while amastigotes 
suffer the effect of the reactive species inside 
mammalian cells. To establish a chronic infection 
some parasites must resist the oxidative damage. 
Although all cellular macromolecules are subject 
to damage, the primary deleterious consequences 
of oxidative stress probably arise from damage to 
DNA. However, to date we are not aware about 
reports showing oxidative damage in T. cruzi DNA. 
Additionally, the capacity as well as the mechanisms 
responsible for the repair of the DNA damage is 
also unknown. We propose that the parasite DNA 
is damaged but it is repaired via the base excision 
repair pathway that is activated when T. cruzi is 
exposed to ROS/RNS, allowing its survival. 
We report that H2O2 and NOO
- induce oxidative 
nuclear and kineplastid DNA damage in T. cruzi 
that may be partially repaired by the parasite. 
Furthermore, we show that both oxidative agents 
diminish cell viability of T. cruzi epimastigotes 
and trypomastigotes. This effect is significantly 
augmented in parasites subsequently incubated 
with the drug methoxyamine, an inhibitor of the 
apurinic/apyrimidinic enzymes involved in the base 
excision repair pathway of DNA repair, suggesting 
that the base excision repair pathway is indeed 
activated after oxidative damage to the parasite. 
The diminution of cell viability after ROS/NOS attack 
is most probably due to a population of parasites 
unable to repair their DNA. On the contrary, the 
maintenance of T. cruzi viability is a consequence of 
DNA repair mechanisms, most probably sustained 
by the base excision repair pathway. 
We have cloned, expressed and identified by 
mass spectrometry three recombinant T. cruzi 
DNA repair enzymes (TcAP1, TcAP2 and NL1Tc). 
As analyzed by modelling, these enzymes present 
structural characteristics similar but not equal to 
mammalian ones. Using an antibody prepared 
against TcAP1 peptides we recognized presence 
of this enzyme in the three cellular forms of the 
parasite. Transfected TcAP1-GFP and TcAP2-GFP 
to epimastigotes show that TcAP1 and TcAP2 are 
localized in the nucleus but not in the kinetoplast 
of the parasite. Overexpression of both enzymes 
independently, increases survival of parasites when 
submitted to oxidative stress.
Our results show that T. cruzi DNA is damaged 
when exposed to H2O2 and NOO
- and that this 
damage is partially repaired by the parasite. 
Inhibition of the base excision repair pathway by 
methoxyamine diminishes parasite viability when 
exposed to oxidative agents. At least two T. cruzi 
enzymes of the base excision repair pathway were 
cloned and expressed. It is proposed that inhibition 
of DNA repair represents a possible therapeutic 
target for the control of T.cruzi infection, particularly 
if this target is articulated with the conventional 
drugs used for Chagas disease treatment.
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